XORTX Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)
Stocks in Play: XORTX Therapeutics Inc.
XORTX Therapeutics Adjusts Warrant Terms
XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection With October 2021 US IPO
07:01 AM EDT, 05/17/2024 (MT Newswires) -- XORTX Therapeutics Brief: Says Repriced Balance of Warrants Issued in Connection with October 2021 US IPO
XORTX Reprices Balance of Warrants Issued in Connection With October 2021 US IPO
CALGARY, Alberta, May 17, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU)), a late stage clinical pharmaceutical company focused on developing
Xortx Therapeutics Q1 Financial Snapshot
XORTX Therapeutics | 20-F: Registration statement / Annual report / Transition report
XORTX Therapeutics Adjusts Warrant Exercise Price
XORTX Announces Publication of Key Research in ADPKD
CALGARY, Alberta, April 22, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
XORTX Therapeutics Boosts Board With Biotech Pro
XORTX Therapeutics Appoints Industry Leader to Board
XORTX Announces Participation in Spring 2024 Investor Conferences
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
Xortx Therapeutics Reports Stable Finances
XORTX Announces New Clinical Advisory Board Member
CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a biopharmaceutical company focused on developing
XORTX: A Year of Milestones and Strategic Advancements as It Readies for a Registration Clinical Trial
XORTX Therapeutics Provides Update
XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company developing therapies to treat progressive kidney disease, on Tuesday provided an overview of its 2023 achievements. The com
XORTX Therapeutics Advances Kidney Disease Program
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
CALGARY, Alberta, March 19, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company
XORTX Therapeutics Announces Warrant Repricing
XORTX Reprices Warrants Issued in Connection With Previous Private Placements
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, March 11, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Compa
No Data